Table 2 Top 5 most common indications of primary cancer in the FAERS database for lenvatinib、pembrolizumab and combination therapy-induced bleeding cases and top 5 indications for which deaths were reported in these bleeding cases
drugs | Tob 5 indications | #of patients | %of patients | #of deaths reported | %of deaths reported |
|---|---|---|---|---|---|
lenvatinib | hepatocellular carcinoma | 506 | 42.81% | 88 | 7.45% |
thyroid cancer | 221 | 18.7% | 46 | 3.89% | |
hepatic cancer | 84 | 7.11% | 11 | 0.93% | |
anaplastic thyroid cancer | 75 | 6.35% | 37 | 3.13% | |
renal cancer | 49 | 4.15% | 2 | 0.17% | |
pembrolizumab | non-small cell lung cancer | 97 | 10.19% | 16 | 1.68% |
uterine cancer | 55 | 5.78% | 2 | 0.21% | |
metastatic malignant melanoma | 46 | 4.83% | 8 | 0.84% | |
endometrial cancer | 41 | 4.31% | 9 | 0.95% | |
transitional cell carcinoma | 40 | 4.2% | 4 | 0.42% | |
combination therapy | endometrial cancer | 142 | 33.81% | 25 | 5.95% |
renal cell carcinoma | 40 | 9.52% | 7 | 1.67% | |
hepatocellular carcinoma | 39 | 9.29% | 3 | 0.71% | |
squamous cell carcinoma of head and neck | 33 | 7.86% | 11 | 2.62% | |
clear cell renal cell carcinoma | 24 | 5.71% | 2 | 0.48% |